Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

WASHINGTON, July 21, 2017 -- (Healthcare Sales & Marketing Network) -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the European Medicines Agency's Committee for Medicinal Product for Human Use (CHMP) has adopted a negative opin... Biopharmaceuticals, Regulatory Vanda Pharmaceuticals, Fanaptum, iloperidone, schizophrenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news